DAA治愈的丙肝代偿期肝硬化伴临床显著门脉高压患者失代偿风险极低
本研究评估直接抗病毒药物(DAA)治愈的Child-A级丙肝肝硬化伴临床显著门脉高压但无高危静脉曲张患者的失代偿发生率。中位随访49个月,148例中仅1例(腹水)失代偿,4年累积风险1%,且失代偿与肝细胞癌相关。提示该人群失代偿风险可忽略,不支持普遍使用非选择性β受体阻滞剂。
要点
- DAA治愈的Child-A级丙肝肝硬化伴临床显著门脉高压患者失代偿风险极低。
- 4年累积失代偿风险仅1%,且失代偿与肝细胞癌相关。
- 该人群普遍使用非选择性β受体阻滞剂预防失代偿的必要性存疑。
核心结论
- DAA治愈的丙肝代偿期Child-A级肝硬化伴临床显著门脉高压但无高危静脉曲张患者失代偿风险可忽略,不支持普遍使用非选择性β受体阻滞剂。
研究设计与样本
- 评估DAA治愈的Child-A级丙肝肝硬化无高危静脉曲张患者失代偿发生率,随访49个月(范围12-60个月),共148例。
主要发现
- 随访期间148例中仅1例发生失代偿(腹水),4年累积风险为1%。
- 失代偿与肝细胞癌相关。
临床怎么用
- 对于DAA治愈的Child-A级丙肝肝硬化伴临床显著门脉高压但无高危静脉曲张患者,可考虑不普遍使用非选择性β受体阻滞剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonselective β-blockers improve decompensation-free survival in viremic hepatitis C virus compensated cirrhotic patients with clinically significant portal hypertension, but their protective role after sustained virological response by direct-acting antiviral (DAA) is undefined. We evaluated the incidence of decompensation in DAA-cured Child-A patients without high-risk varices. During the 49-month (12-60) follow-up, only one of 148 patients decompensated (ascites), with a 4-year cumulative risk of 1%, but decompensation was associated with hepatocellular carcinoma. The risk of decompensation in DAA cured hepatitis C virus compensated Child-A cirrhotic patients with clinically significant portal hypertension but without high-risk varices is negligible; thus, questioning the need for nonselective β-blocker treatment in this setting (see Visual abstract, Supplemental Digital Content, 1, http://links.lww.com/AJG/B861). JOURNAL/ajgast/04.03/00000434-202106000-00035/inline-graphic1/v/2021-05-28T144026Z/r/image-tiff.
引用
- Tosetti G, Degasperi E, Farina E, et al. Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy. Am J Gastroenterol. 2021. PMID: 33606382. doi:10.14309/ajg.0000000000001158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。